215 related articles for article (PubMed ID: 18509642)
1. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.
Guo J; Parise RA; Joseph E; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
Cancer Chemother Pharmacol; 2009 Mar; 63(4):615-25. PubMed ID: 18509642
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
Clausen DM; Guo J; Parise RA; Beumer JH; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
J Pharmacol Exp Ther; 2010 Dec; 335(3):715-27. PubMed ID: 20801893
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.
Wang J; Ma X; Jones HM; Chan LL; Song F; Zhang W; Bae-Jump VL; Zhou C
J Transl Med; 2014 Aug; 12():226. PubMed ID: 25143136
[TBL] [Abstract][Full Text] [Related]
4. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.
Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson LG
Sci Rep; 2018 Jul; 8(1):10064. PubMed ID: 29968736
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
6. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.
Guo J; Clausen DM; Beumer JH; Parise RA; Egorin MJ; Bravo-Altamirano K; Wipf P; Sharlow ER; Wang QJ; Eiseman JL
Cancer Chemother Pharmacol; 2013 Feb; 71(2):331-44. PubMed ID: 23108699
[TBL] [Abstract][Full Text] [Related]
8. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
9. Stopping MYC in its tracks.
Stefan E; Hart JR; Bister K
Aging (Albany NY); 2015 Jul; 7(7):463-4. PubMed ID: 26187009
[No Abstract] [Full Text] [Related]
10. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.
Shi J; Stover JS; Whitby LR; Vogt PK; Boger DL
Bioorg Med Chem Lett; 2009 Nov; 19(21):6038-41. PubMed ID: 19800226
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma.
Zhang M; Fan HY; Li SC
Biomed Pharmacother; 2015 Jul; 73():123-8. PubMed ID: 26211592
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
13. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule modulators of c-Myc/Max and Max/Max interactions.
Berg T
Curr Top Microbiol Immunol; 2011; 348():139-49. PubMed ID: 20680803
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization.
Lu X; Vogt PK; Boger DL; Lunec J
Oncol Rep; 2008 Mar; 19(3):825-30. PubMed ID: 18288422
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
Struntz NB; Chen A; Deutzmann A; Wilson RM; Stefan E; Evans HL; Ramirez MA; Liang T; Caballero F; Wildschut MHE; Neel DV; Freeman DB; Pop MS; McConkey M; Muller S; Curtin BH; Tseng H; Frombach KR; Butty VL; Levine SS; Feau C; Elmiligy S; Hong JA; Lewis TA; Vetere A; Clemons PA; Malstrom SE; Ebert BL; Lin CY; Felsher DW; Koehler AN
Cell Chem Biol; 2019 May; 26(5):711-723.e14. PubMed ID: 30880155
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.
Jeong KC; Ahn KO; Yang CH
Mol Biosyst; 2010 Aug; 6(8):1503-9. PubMed ID: 20485733
[TBL] [Abstract][Full Text] [Related]
19. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.
Zirath H; Frenzel A; Oliynyk G; Segerström L; Westermark UK; Larsson K; Munksgaard Persson M; Hultenby K; Lehtiö J; Einvik C; Påhlman S; Kogner P; Jakobsson PJ; Henriksson MA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10258-63. PubMed ID: 23733953
[TBL] [Abstract][Full Text] [Related]
20. The interferon- and differentiation-inducible p202a protein inhibits the transcriptional activity of c-Myc by blocking its association with Max.
Wang H; Liu C; Lu Y; Chatterjee G; Ma XY; Eisenman RN; Lengyel P
J Biol Chem; 2000 Sep; 275(35):27377-85. PubMed ID: 10835425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
